7 Jun 2018

New UCB Data Presented at the Annual European Congress of Rheumatology (EULAR 2018) Serves Key Patient Populations Including Ankylosing Spondylitis, Psoriatic Arthritis, and Women with Chronic Inflammatory Diseases

Read More
1 Jun 2018

UCB receives CHMP positive opinion for adjunctive use of BRIVIACT® as paediatric treatment for epilepsy patients

Read More
27 May 2018

UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.

Read More
23 May 2018

U.S. Court of Appeals confirms validity of patent for UCB's Vimpat®

Read More
21 May 2018

UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority

Read More
15 May 2018

CIMZIA® (certolizumab pegol) is The First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

Read More
13 May 2018

UCB announces BRIVIACT® (brivaracetam) now approved by FDA to treat partial-onset (focal) seizures in pediatric epilepsy patients

Read More
10 May 2018

UCB to present latest epilepsy scientific data and research perspectives at EILAT Conference

Read More
27 Apr 2018

UCB Announces Positive CHMP Opinion for CIMZIA® (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis 

Read More
26 Apr 2018

UCB's General Meeting of Shareholders

Read More
Subscribe to